FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Camber Capital Management LLC

2. Date of Event Requiring Statement (MM/DD/YYYY)
10/15/2015 

3. Issuer Name and Ticker or Trading Symbol

Protalix BioTherapeutics, Inc. [PLX]

(Last)        (First)        (Middle)

101 HUNTINGTON AVENUE, SUITE 2550

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                            ___ X ___ 10% Owner
_____ Officer (give title below)          _____ Other (specify below)

(Street)

BOSTON, MA 02199       

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed (MM/DD/YYYY)

 

6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person


Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4) 		2. Amount of Securities Beneficially Owned
(Instr. 4) 		3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5) 		4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock   9274577   I   See Footnotes   (1) (2)
Convertible Note Contracts   1562933   I   See Footnotes   (1) (3)

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4) 		2. Date Exercisable and Expiration Date
(MM/DD/YYYY) 		3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4) 		4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5) 		6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
( 1)  Securities reported herein for Camber Capital Management LLC (the "LLC" ) represent Common Stock and Convertible Note Contracts (on an as-coverted basis) beneficially owned and held of record by Camber Capital Master Fund, L.P. (the "Fund"), another private investment fund (the "Fund") and one managed account (the "Managed Account") for which the LLC serves as the investment manager. Stephen DuBois is the managing member of the LLC and managing member of the general partner for the Fund and the Master Fund. The LLC, the Master Fund, the Fund, the Managed Account, general partner and Mr. DuBois (the "Reporting Persons") are each beneficial owners and have an address of 101 Huntington Avenue, Floor 25, Boston, MA 02199. The Reporting Persons disclaim beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the shares in which the Reporting Persons have no actual pecuniary interest therein.
( 2)  Of the securities reported herein, 8,953,095 shares of Common Stock are held for the account of the Master Fund, 63,057 shares of Common Stock are held for the account of the Fund, and 258,425 shares of Common Stock are held for the account of the Managed Account.
( 3)  Of the securities reported herein, 8,541 Convertible Note Contracts (equivalent to 1,483,224 shares of Common Stock on an as-coverted basis) are held for the account of the Master Fund, 68 Convertible Note Contracts (equivalent to 11,878 shares of Common Stock on an as-coverted basis) are held for the account of the Fund, and 391 Convertible Note Contracts (equivalent to 67,831 shares of Common Stock on an as-coverted basis) are held for the account of the Managed Account.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Camber Capital Management LLC
101 HUNTINGTON AVENUE
SUITE 2550
BOSTON, MA 02199
X


Signatures
Stephen DuBois 10/20/2015
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Protalix BioTherapeutics (AMEX:PLX)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Protalix BioTherapeutics Charts.
Protalix BioTherapeutics (AMEX:PLX)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Protalix BioTherapeutics Charts.